Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein

Journal of Immunology

Volumn 156, Issue 9, 1996, Pages 3151-3158

  Disis, Mary L ^a,b   Gralow, Julie R ^a   Bernhard, Helga ^a   Hand, Susan L ^a   Rubin, William D ^a   Cheever, Martin A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Division of Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; AUTOIMMUNITY; CANCER; CANCER IMMUNOLOGY; CANCER PREVENTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; RAT; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; HUMANS; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PRECIPITIN TESTS; RATS; RATS, INBRED F344; RECEPTOR, ERBB-2; T-LYMPHOCYTES; VACCINES;

EID: 0030004598     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Coussens, L., T. L. Yang-Feng, Y. L. E. Chen, A. Gray, J. McGrath, P. H. Seeburg, T. A. Liberman, J. Schlessinger, U. Francke, A. Levinson, and A. Ullrich. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132.
2. Slamon, D., G. Clark, S. Wong, W. Levin, A. Ullrich, and W. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177.
3. Gusterson, B., R. Gelber, A. Goldhirsch, K. Price, J. Save-Soderborgh, R. Anbazhagan, J. Styles, C. Rudenstam, R. Golouh, R. Reed, F. Martinez-Tello, A. Tiltman, J. Torhorst, P. Grigolato, R. Bettelheim, A. Neville, K. Bürki, M. Castiglione, J. Collins, J. Lindtner, and H.-J. Senn. 1992. Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol. 10:1049.
4. Allred, D., G. Clark, R. Molina, A. Tandon, S. Schnitt, K. Gilchrist, C. Osborne, D. Tormey, and W. McGuire. 1992. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol. 23:974.
5. Bernards, R., A. Destree, S. McKenzie, E. Gordon, R. A. Weinberg and D. Panicali. 1987. Effective tumor immunotherapy directed against an oncogene-encoded product using a vacinnia virus vector. Proc. Natl. Acad. Sci. USA 84:6854.
6. Disis, M. L., E. Calenoff, G. McLaughlin, A. E. Murphy, W. Chen, B. Groner, M. Jeschke, N. Lydon, E. McGlynn, R. B. Livingston, R. Moe, and M. A. Cheever. 1994. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54:16.
7. Fisk, B., T. L. Blevins, J. T. Wharton, and C. G. Ioannides. 1995. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor specific cytotoxic T lymphocyte lines. J. Exp. Med. 181:2109.
8. Peoples, G. E., P. S. Goedegebuure, R. Smith, D. C. Linehan, I. Yoshino, and T. J. Eberlein. 1995. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER-2/neu-derived peptide. Proc. Natl. Acad. Sci. USA 92: 432.
9. Sercarz, E. E., P. V. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11:729.
10. Cibotti, R., J. M. Kanellopoulos, J. P. Cabaniols, O. Halle-Panenko, K. Kosmatopoulos, E. Sercarz, and P. Kourilsky. 1992. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. USA 89:416.
11. Feller, D., and V. F. de la Cruz. 1991. Identifying antigenic T cell sites. Nature 349:720.
12. Ioannides, C. G., and T. L. Whiteside. 1993. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin. Immunol. Immunopathol. 66:91.
13. Yamamoto, T., S. Ikawa, T. Akiyama, K. Semba, N. Nomura, N. Miyajima, T. Saito, and K. Toyoshima. 1986. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230.
14. Chicz, R. M., R. G. Urban, J. C. Gorga, D. A. Vignali, W. S. Lane, and J. L. Strominger. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27.
15. Pardoll, D. M. 1994. A new look for the 1990s, Nature 369:357.
16. Houghton, A. N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1.